Dr. Ciara Catherine O'Sullivan, MD

Dr. O'Sullivan practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. O'Sullivan's NPI, 1427495357, was assigned on June 1, 2013. Dr. O'Sullivan graduated from University College of Dublin National Univ SOM in 2005. Dr. O'Sullivan holds Minnesota license 60300.

Dr. O'Sullivan's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. O'Sullivan's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. O'Sullivan is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. O'Sullivan to 1 more hospital, 1 clinical lab and 1 hospice, each named with a free account. Dr. O'Sullivan's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Sullivan practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. O'Sullivan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. O'Sullivan's licenses on file in 2 states: Minnesota and District of Columbia.

Dmand AI lists breast cancer among the conditions Dr. O'Sullivan treats.

CMS data shows 15,492 Medicare services from Dr. O'Sullivan across 23 procedure codes in 2024, for 268 Medicare patients. Medicare paid $307,086 for them. Every service was in an office.

CMS counts 268 Medicare patients who saw Dr. O'Sullivan in 2024. The largest group is 65 to 74, with 140 patients. 65% of them have cancer, and 59% have high blood pressure. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Sullivan's median patient age at 64, with 80% women.

In 2024, Dr. O'Sullivan wrote 231 Medicare Part D claims for 62 patients. 81% of them were for generic drugs. CMS names the drug for 190 of them, across 7 drugs with 11 or more claims each, at $567,696 in total drug cost. In 2023, CMS named 83 claims across 3 drugs.

Dr. O'Sullivan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Sullivan as offering telehealth.

Dmand AI links 52 papers to Dr. O'Sullivan, published from 2013 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Receptor, ErbB-2 and Antineoplastic Agents. Dr. O'Sullivan has published most often in Breast Cancer Res Treat. Dr. O'Sullivan's most frequent co-authors are Tufia Christine Haddad, MD, Kathryn Jean Ruddy, MD, MPH and Charles L. Loprinzi, MD.

Dmand AI links Dr. O'Sullivan to 10 clinical trials, 5 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Chordoma. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. O'Sullivan that name 1 trial.

CMS Open Payments shows 19 general payments to Dr. O'Sullivan from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 84% of the total. AstraZeneca Pharmaceuticals LP paid the most, $11,463. It also lists 5 research payments totaling $21,330 from 2018 to 2025, naming 1 clinical trial.

Dr. O'Sullivan graduated from University College of Dublin National Univ SOM in 2005.

Dr. O'Sullivan is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.